Halozyme Therapeutics, Inc. (NASDAQ:HALO) Shares Purchased by American Century Companies Inc.

American Century Companies Inc. lifted its holdings in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) by 1.8% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 866,366 shares of the biopharmaceutical company's stock after buying an additional 15,079 shares during the period. American Century Companies Inc. owned about 0.68% of Halozyme Therapeutics worth $41,421,000 at the end of the most recent reporting period.

Other hedge funds have also modified their holdings of the company. Heck Capital Advisors LLC purchased a new position in Halozyme Therapeutics in the fourth quarter worth $29,000. CBIZ Investment Advisory Services LLC purchased a new position in shares of Halozyme Therapeutics in the 4th quarter valued at about $29,000. Smartleaf Asset Management LLC lifted its stake in shares of Halozyme Therapeutics by 29.2% in the fourth quarter. Smartleaf Asset Management LLC now owns 871 shares of the biopharmaceutical company's stock valued at $42,000 after purchasing an additional 197 shares during the period. Venturi Wealth Management LLC purchased a new stake in Halozyme Therapeutics during the fourth quarter worth about $69,000. Finally, Parkside Financial Bank & Trust grew its position in Halozyme Therapeutics by 21.8% during the fourth quarter. Parkside Financial Bank & Trust now owns 1,800 shares of the biopharmaceutical company's stock worth $86,000 after buying an additional 322 shares during the period. 97.79% of the stock is owned by institutional investors and hedge funds.

Halozyme Therapeutics Trading Down 3.0 %

NASDAQ:HALO traded down $1.94 on Tuesday, reaching $61.87. The stock had a trading volume of 1,407,707 shares, compared to its average volume of 1,380,663. The company has a market cap of $7.64 billion, a price-to-earnings ratio of 18.04, a P/E/G ratio of 0.42 and a beta of 1.32. Halozyme Therapeutics, Inc. has a 12-month low of $37.73 and a 12-month high of $66.00. The company has a debt-to-equity ratio of 4.14, a current ratio of 7.80 and a quick ratio of 9.15. The firm's fifty day moving average is $59.34 and its two-hundred day moving average is $54.84.

Remove Ads

Halozyme Therapeutics (NASDAQ:HALO - Get Free Report) last announced its quarterly earnings data on Tuesday, February 18th. The biopharmaceutical company reported $1.19 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.17 by $0.02. The business had revenue of $298.01 million for the quarter, compared to the consensus estimate of $285.74 million. Halozyme Therapeutics had a net margin of 43.74% and a return on equity of 157.78%. Equities analysts expect that Halozyme Therapeutics, Inc. will post 4.73 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

HALO has been the topic of several research analyst reports. Piper Sandler boosted their price target on Halozyme Therapeutics from $52.00 to $53.00 and gave the stock a "neutral" rating in a research note on Friday, January 10th. Benchmark reiterated a "buy" rating and set a $75.00 target price on shares of Halozyme Therapeutics in a research report on Thursday, February 20th. HC Wainwright restated a "buy" rating on shares of Halozyme Therapeutics in a research report on Thursday, March 6th. Finally, Wells Fargo & Company decreased their price objective on shares of Halozyme Therapeutics from $62.00 to $57.00 and set an "equal weight" rating on the stock in a research report on Monday, January 13th. Four research analysts have rated the stock with a hold rating and six have given a buy rating to the company's stock. Based on data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average price target of $62.78.

Insider Activity

In other Halozyme Therapeutics news, SVP Michael J. Labarre sold 1,697 shares of the stock in a transaction that occurred on Thursday, February 27th. The shares were sold at an average price of $58.28, for a total transaction of $98,901.16. Following the transaction, the senior vice president now owns 173,756 shares of the company's stock, valued at $10,126,499.68. This trade represents a 0.97 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director Jeffrey William Henderson sold 503 shares of the business's stock in a transaction on Tuesday, April 1st. The shares were sold at an average price of $64.05, for a total transaction of $32,217.15. Following the sale, the director now directly owns 33,108 shares of the company's stock, valued at $2,120,567.40. This represents a 1.50 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 32,200 shares of company stock valued at $1,786,668 over the last quarter. Company insiders own 2.40% of the company's stock.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.